认知虚弱和衰老:临床特征,病理生理机制和潜在的预防策略
Sara Gloria Aguilar-Navarro1, Alberto José Mimenza-Alvarado1, Sara Gabriela Yeverino-Castro2
1Department of Geriatrics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Archives of medical research
|November 10, 2024
概括
认知虚弱 (CF) 将身体虚弱与痴呆症之前的认知衰退联系在一起. 早期检测和多领域干预,如认知和体育训练,对于管理这种情况至关重要.
科学领域:
- 老年学是指老年学的学科.
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
背景情况:
- 脆弱性越来越被认为是一种多领域的疾病,超越身体衰退,包括认知障碍和心理社会因素.
- 轻度认知障碍是一种痴呆前阶段,其特点是记忆或其他认知领域的缺陷.
- 认知脆弱性 (CF) 被提出为一种结构,将身体脆弱性与非痴呆的认知衰退相结合.
研究的目的:
- 介绍和定义认知虚弱 (CF) 的概念.
- 突出了对CF早期检测策略的需要.
- 讨论CF的病理生理基础和潜在干预措施.
主要方法:
- 摘要综合了现有的文献和概念框架来定义CF.
- 它审查了导致CF的病理生理机制.
- 它讨论了当前的非药物和多领域干预策略.
主要成果:
- 据估计,CF的患病率范围广泛,从10.3%到42.8%.
- 病理生理成分包括应激反应失调,代谢失衡,心血管问题,线粒体功能障碍和动脉硬.
- 细胞变化涉及氨酸- ангиотензин- алдостерон系统,炎症,内皮功能障碍和氧化应激.
结论:
- 认知虚弱代表了明显痴呆症之前的关键阶段,需要及时识别.
- 多领域干预措施,特别是认知和体育训练,显示出预防和治疗的前景.
- 临床医生承认CF是一个有效的概念,需要基于证据的管理策略.
相关概念视频
Cognitive Development During Adulthood
58
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
58
Aging
37
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
37
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Dementia
97
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
97
The Effect of Aging on Tissues
2.1K
Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
2.1K
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165


